Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2008

01.07.2008 | Epidemiology

Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years

verfasst von: Jiachun Lu, Qingyi Wei, Melissa L. Bondy, Abenaa M. Brewster, Therese B. Bevers, Tse-Kuan Yu, Thomas A. Buchholz, Funda Meric-Bernstam, Kelly K. Hunt, S. Eva Singletary, Li-E Wang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

The histone protein family member X (H2AFX) is important in maintaining chromatin structure and genetic stability. Genetic variants in H2AFX may alter protein functions and thus cancer risk. In this case-control study, we genotyped four common single nucleotide polymorphisms (i.e., −1654A > G [rs643788], −1420G > A [rs8551], and −1187T > C [rs7759] in the H2AFX promoter region and 1057C > T [rs7350] in the 3′ untranslated region (UTR)) in 467 patients with sporadic breast cancer and 488 cancer-free controls. All female subjects were non-Hispanic whites aged ≤55 years. We found that significantly increased risk of breast cancer was associated with variant genotypes in the H2AFX promoter: adjusted odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.38–2.34 for −1654AG/GG; OR = 1.40, 95% CI = 1.07–1.83 for −1420GA/AA; and OR = 1.65, 95% CI = 1.26–2.16 for −1187TC/CC. Furthermore, the number of variant alleles in the promoter haplotypes was associated with increased risks of breast cancer in a dose-response manner (OR = 6.08, 95% CI = 3.25–11.38; OR = 6.83, 95% CI = 3.83–12.18; and OR = 23.61, 95% CI = 3.95–140.99 for one, two, and three variant alleles, respectively) (P trend < 0.0001). Age at onset of breast cancer significantly decreased as the number of variant alleles increased (P trend = 0.024). However, these effects were not observed in the 3′UTR 1057C > T polymorphism. Therefore, we believe that H2AFX promoter polymorphisms may contribute to the etiology of sporadic breast cancer in young non-Hispanic white women. Larger association studies and related functional studies are warranted to confirm these findings.
Literatur
1.
Zurück zum Zitat Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251–260PubMedCrossRef Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251–260PubMedCrossRef
2.
Zurück zum Zitat Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858–5868PubMedCrossRef Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858–5868PubMedCrossRef
3.
Zurück zum Zitat Ivanova VS, Hatch CL, Bonner WM (1994) Characterization of the human histone H2A.X gene. Comparison of its promoter with other H2A gene promoters. J Biol Chem 269:24189–24194PubMed Ivanova VS, Hatch CL, Bonner WM (1994) Characterization of the human histone H2A.X gene. Comparison of its promoter with other H2A gene promoters. J Biol Chem 269:24189–24194PubMed
4.
Zurück zum Zitat Ivanova VS, Zimonjic D, Popescu N, Bonner WM (1994) Chromosomal localization of the human histone H2A.X gene to 11q23.2-q23.3 by fluorescence in situ hybridization. Hum Genet 94:303–306PubMedCrossRef Ivanova VS, Zimonjic D, Popescu N, Bonner WM (1994) Chromosomal localization of the human histone H2A.X gene to 11q23.2-q23.3 by fluorescence in situ hybridization. Hum Genet 94:303–306PubMedCrossRef
5.
Zurück zum Zitat Bassing CH, Chua KF, Sekiguchi J, Suh H, Whitlow SR, Fleming JC, Monroe BC, Ciccone DN, Yan C, Vlasakova K, Livingston DM, Ferguson DO, Scully R, Alt FW (2002) Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA 99:8173–8178PubMedCrossRef Bassing CH, Chua KF, Sekiguchi J, Suh H, Whitlow SR, Fleming JC, Monroe BC, Ciccone DN, Yan C, Vlasakova K, Livingston DM, Ferguson DO, Scully R, Alt FW (2002) Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA 99:8173–8178PubMedCrossRef
6.
Zurück zum Zitat Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA, Reina-San-Martin B, Coppola V, Meffre E, Difilippantonio MJ, Redon C, Pilch DR, Olaru A, Eckhaus M, Camerini-Otero RD, Tessarollo L, Livak F, Manova K, Bonner WM, Nussenzweig MC, Nussenzweig A (2002) Genomic instability in mice lacking histone H2AX. Science 296:922–927PubMedCrossRef Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA, Reina-San-Martin B, Coppola V, Meffre E, Difilippantonio MJ, Redon C, Pilch DR, Olaru A, Eckhaus M, Camerini-Otero RD, Tessarollo L, Livak F, Manova K, Bonner WM, Nussenzweig MC, Nussenzweig A (2002) Genomic instability in mice lacking histone H2AX. Science 296:922–927PubMedCrossRef
7.
Zurück zum Zitat Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA, Eckhaus M, Ried T, Bonner WM, Nussenzweig A (2003) H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114:371–383PubMedCrossRef Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA, Eckhaus M, Ried T, Bonner WM, Nussenzweig A (2003) H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114:371–383PubMedCrossRef
8.
Zurück zum Zitat Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M, Gleason M, Bronson R, Lee C, Alt FW (2003) Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114:359–370PubMedCrossRef Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M, Gleason M, Bronson R, Lee C, Alt FW (2003) Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114:359–370PubMedCrossRef
9.
Zurück zum Zitat Ralhan R, Kaur J, Kreienberg R, Wiesmuller L (2007) Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett 248:1–17PubMedCrossRef Ralhan R, Kaur J, Kreienberg R, Wiesmuller L (2007) Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett 248:1–17PubMedCrossRef
10.
Zurück zum Zitat Zhang C, Naftalis E, Euhus D (2006) Carcinogen-induced DNA double strand break repair in sporadic breast cancer. J Surg Res 135:120–128PubMedCrossRef Zhang C, Naftalis E, Euhus D (2006) Carcinogen-induced DNA double strand break repair in sporadic breast cancer. J Surg Res 135:120–128PubMedCrossRef
11.
Zurück zum Zitat Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247–254PubMedCrossRef Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247–254PubMedCrossRef
12.
Zurück zum Zitat Abbott DW, Freeman ML, Holt JT (1998) Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90:978–985PubMedCrossRef Abbott DW, Freeman ML, Holt JT (1998) Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90:978–985PubMedCrossRef
13.
Zurück zum Zitat Rosen EM, Fan S, Pestell RG, Goldberg ID (2003) BRCA1 gene in breast cancer. J Cell Physiol 196:19–41PubMedCrossRef Rosen EM, Fan S, Pestell RG, Goldberg ID (2003) BRCA1 gene in breast cancer. J Cell Physiol 196:19–41PubMedCrossRef
14.
Zurück zum Zitat Ting NS, Lee WH (2004) The DNA double-strand break response pathway: becoming more BRCAish than ever. DNA Repair (Amst) 3:935–944CrossRef Ting NS, Lee WH (2004) The DNA double-strand break response pathway: becoming more BRCAish than ever. DNA Repair (Amst) 3:935–944CrossRef
16.
Zurück zum Zitat Vilenchik MM, Knudson AG (2003) Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci USA 100:12871–12876PubMedCrossRef Vilenchik MM, Knudson AG (2003) Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci USA 100:12871–12876PubMedCrossRef
17.
Zurück zum Zitat Kaufmann WK, Filatov L, Oglesbee SE, Simpson DA, Lotano MA, McKeen HD, Sawyer LR, Moore DT, Millikan RC, Cordeiro-Stone M, Carey LA (2006) Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. Carcinogenesis 27:2519–2527PubMedCrossRef Kaufmann WK, Filatov L, Oglesbee SE, Simpson DA, Lotano MA, McKeen HD, Sawyer LR, Moore DT, Millikan RC, Cordeiro-Stone M, Carey LA (2006) Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. Carcinogenesis 27:2519–2527PubMedCrossRef
18.
Zurück zum Zitat Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, Wang LE (2006) Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women < = 55 years. Carcinogenesis 27:2209–2216PubMedCrossRef Lu J, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Meric-Bernstam F, Hunt KK, Singletary SE, Ross MI, Wang LE (2006) Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women < = 55 years. Carcinogenesis 27:2209–2216PubMedCrossRef
19.
Zurück zum Zitat Shi Q, Wang LE, Bondy ML, Brewster A, Singletary SE, Wei Q (2004) Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis 25:1695–1700PubMedCrossRef Shi Q, Wang LE, Bondy ML, Brewster A, Singletary SE, Wei Q (2004) Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis 25:1695–1700PubMedCrossRef
20.
Zurück zum Zitat Xiong P, Bondy ML, Li D, Shen H, Wang LE, Singletary SE, Spitz MR, Wei Q (2001) Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case-control study. Cancer Res 61:8465–8469PubMed Xiong P, Bondy ML, Li D, Shen H, Wang LE, Singletary SE, Spitz MR, Wei Q (2001) Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case-control study. Cancer Res 61:8465–8469PubMed
21.
Zurück zum Zitat Monteiro AN, Zhang S, Phelan CM, Narod SA (2003) Absence of constitutional H2AX gene mutations in 101 hereditary breast cancer families. J Med Genet 40:e51PubMedCrossRef Monteiro AN, Zhang S, Phelan CM, Narod SA (2003) Absence of constitutional H2AX gene mutations in 101 hereditary breast cancer families. J Med Genet 40:e51PubMedCrossRef
22.
Zurück zum Zitat Walsh SH, Rosenquist R (2005) Absence of H2AX gene mutations in B-cell leukemias and lymphomas. Leukemia 19:464PubMedCrossRef Walsh SH, Rosenquist R (2005) Absence of H2AX gene mutations in B-cell leukemias and lymphomas. Leukemia 19:464PubMedCrossRef
23.
Zurück zum Zitat Wilkie GS, Dickson KS, Gray NK (2003) Regulation of mRNA translation by 5′- and 3′-UTR-binding factors. Trends Biochem Sci 28:182–188PubMedCrossRef Wilkie GS, Dickson KS, Gray NK (2003) Regulation of mRNA translation by 5′- and 3′-UTR-binding factors. Trends Biochem Sci 28:182–188PubMedCrossRef
24.
Zurück zum Zitat Buckland PR, Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O’Donovan MC (2005) Strong bias in the location of functional promoter polymorphisms. Hum Mutat 26:214–223PubMedCrossRef Buckland PR, Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O’Donovan MC (2005) Strong bias in the location of functional promoter polymorphisms. Hum Mutat 26:214–223PubMedCrossRef
25.
Zurück zum Zitat Ponomarenko JV, Merkulova TI, Vasiliev GV, Levashova ZB, Orlova GV, Lavryushev SV, Fokin ON, Ponomarenko MP, Frolov AS, Sarai A (2001) rSNP_Guide, a database system for analysis of transcription factor binding to target sequences: application to SNPs and site-directed mutations. Nucleic Acids Res 29:312–316PubMedCrossRef Ponomarenko JV, Merkulova TI, Vasiliev GV, Levashova ZB, Orlova GV, Lavryushev SV, Fokin ON, Ponomarenko MP, Frolov AS, Sarai A (2001) rSNP_Guide, a database system for analysis of transcription factor binding to target sequences: application to SNPs and site-directed mutations. Nucleic Acids Res 29:312–316PubMedCrossRef
26.
Zurück zum Zitat Buckland PR (2006) The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim Biophys Acta 1762:17–28PubMed Buckland PR (2006) The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim Biophys Acta 1762:17–28PubMed
27.
Zurück zum Zitat De Gobbi M, Viprakasit V, Hughes JR, Fisher C, Buckle VJ, Ayyub H, Gibbons RJ, Vernimmen D, Yoshinaga Y, de Jong P, Cheng JF, Rubin EM, Wood WG, Bowden D, Higgs DR (2006) A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 312:1215–1217PubMedCrossRef De Gobbi M, Viprakasit V, Hughes JR, Fisher C, Buckle VJ, Ayyub H, Gibbons RJ, Vernimmen D, Yoshinaga Y, de Jong P, Cheng JF, Rubin EM, Wood WG, Bowden D, Higgs DR (2006) A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 312:1215–1217PubMedCrossRef
28.
Zurück zum Zitat Novik KL, Spinelli JJ, Macarthur AC, Shumansky K, Sipahimalani P, Leach S, Lai A, Connors JM, Gascoyne RD, Gallagher RP, Brooks-Wilson AR (2007) Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 16:1098–1106PubMedCrossRef Novik KL, Spinelli JJ, Macarthur AC, Shumansky K, Sipahimalani P, Leach S, Lai A, Connors JM, Gascoyne RD, Gallagher RP, Brooks-Wilson AR (2007) Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 16:1098–1106PubMedCrossRef
30.
Zurück zum Zitat Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ (2006) c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 37:668–674PubMedCrossRef Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ (2006) c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 37:668–674PubMedCrossRef
31.
Zurück zum Zitat Whelan J, Cordle SR, Henderson E, Weil PA, Stein R (1990) Identification of a pancreatic beta-cell insulin gene transcription factor that binds to and appears to activate cell-type-specific expression: its possible relationship to other cellular factors that bind to a common insulin gene sequence. Mol Cell Biol 10:1564–1572PubMed Whelan J, Cordle SR, Henderson E, Weil PA, Stein R (1990) Identification of a pancreatic beta-cell insulin gene transcription factor that binds to and appears to activate cell-type-specific expression: its possible relationship to other cellular factors that bind to a common insulin gene sequence. Mol Cell Biol 10:1564–1572PubMed
32.
Zurück zum Zitat Rose DP, Komninou D, Stephenson GD (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5:153–165PubMedCrossRef Rose DP, Komninou D, Stephenson GD (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5:153–165PubMedCrossRef
33.
Zurück zum Zitat Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98:303–309PubMedCrossRef Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98:303–309PubMedCrossRef
34.
Zurück zum Zitat Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218–228PubMedCrossRef Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218–228PubMedCrossRef
35.
Zurück zum Zitat Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103:2241–2251PubMedCrossRef Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI (2005) Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103:2241–2251PubMedCrossRef
36.
Zurück zum Zitat Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D’Cruz CM, Chodosh LA (2006) Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res 66:6421–6431PubMedCrossRef Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D’Cruz CM, Chodosh LA (2006) Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res 66:6421–6431PubMedCrossRef
37.
Zurück zum Zitat Li SL, Schlegel W, Valente AJ, Clark RA (1999) Critical flanking sequences of PU.1 binding sites in myeloid-specific promoters. J Biol Chem 274:32453–32460PubMedCrossRef Li SL, Schlegel W, Valente AJ, Clark RA (1999) Critical flanking sequences of PU.1 binding sites in myeloid-specific promoters. J Biol Chem 274:32453–32460PubMedCrossRef
38.
Zurück zum Zitat Marecki S, McCarthy KM, Nikolajczyk BS (2004) PU.1 as a chromatin accessibility factor for immunoglobulin genes. Mol Immunol 40:723–731PubMedCrossRef Marecki S, McCarthy KM, Nikolajczyk BS (2004) PU.1 as a chromatin accessibility factor for immunoglobulin genes. Mol Immunol 40:723–731PubMedCrossRef
39.
Zurück zum Zitat Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG (2002) Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100:998–1007PubMedCrossRef Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG (2002) Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100:998–1007PubMedCrossRef
Metadaten
Titel
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged ≤55 years
verfasst von
Jiachun Lu
Qingyi Wei
Melissa L. Bondy
Abenaa M. Brewster
Therese B. Bevers
Tse-Kuan Yu
Thomas A. Buchholz
Funda Meric-Bernstam
Kelly K. Hunt
S. Eva Singletary
Li-E Wang
Publikationsdatum
01.07.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9717-2

Weitere Artikel der Ausgabe 2/2008

Breast Cancer Research and Treatment 2/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.